Posted on 03/28/2020 9:21:58 AM PDT by Raymond Pamintuan
Abstract We need an effective treatment to cure COVID-19 patients and to decrease the virus carriage duration. In 80 in-patients receiving a combination of hydroxychloroquine and azithromycin we noted a clinical improvement in all but one 86 year-old patient who died, and one 74 year old patient still in intensive care unit. A rapid fall of nasopharyngeal viral load tested by qPCR was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% patients at Day5. This allowed patients to rapidly de discharge from highly contagious wards with a mean length of stay of five days. We believe other teams should urgently evaluate this cost-effective therapeutic strategy, to both avoid the spread of the disease and treat patients as soon as possible before severe respiratory irreversible complications take hold.
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study Running title: Hydroxychloroquine-Azithromycin and COVID-19
https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf
Because they OD'd and took enough to be a fatal dose. I saw another article which gave the amount, which was lethal.
“Impressive results across a decent cohort.
The only thing missing is a control group. Why no control group?”
I think the control group in effect was the study in Hong Kong-
https://www.thelancet.com/action/showPdf?pii=S1473-3099%2820%2930196-1
The Hong Kong study is cited as reference number 22 in the Raoult et. al. paper.
The Hong Kong study found detectable viral load for 20 days on average in patients not receiving Choroquine/azithromycin.
It also found that there was no correlation between the severity of the symptoms and the length of time for which patients had detectable viral load. So the shorter time to elimination of detectable viral infection in the Raoult et. al. study is not due to its patients having less or more severe cases of the infection. There are other benefits to having a new control group studied but in this case there was a pretty good control group identified. A better study would be double blind (use of placebos for the control group, patients/doctors don’t know who is getting a placebo and who isn’t), I would think that is the next step.
https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf
Because ramping up chemical production is (much) more complicated and takes longer. Trump has already addressed this, and activated emergency powers authorizing release of military stores to civilian use. Think about how many doses the DOD has to keep in reserve when, at any time, they may have to send thousands of troops into malarial zones.
Those extra doses will buy us time to get the production lines expanded to accommodate the increased demand.
And in full agreement with the statistics from the French study...full cure in six days.
Quote: Based on two deaths? Or are you being sarc. :-)
Sorry, forgot the /s
But yes, totally sarc. Pretty sure there are some other ingredients in that cleaner that werent on the COVID-19 therapeutic list.
“And in full agreement with the statistics from the French study...full cure in six days.”
Correct.
Yes.
She specifically said “Plaquenil” which is hydroxychloquine
You dont want to kill your control group by giving them placebo. Doctors already know quite well what happens to people who get no treatment.
You didnt read the rest of the thread before posting.
It’s an FR tradition to not even read the article. You want me to read the thread?
Well, you have me on that.
I explained how you could have taken a random sample of similar cases and tracked their progress. The issue is you might not really save anyone...just improve the results marginally.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.